Ozempic and Trazodone Interaction: What Patients and Prescribers Need to Know

What Kind of Interaction Exists Between Ozempic and Trazodone?

The combination produces a pharmacodynamic interaction, not a pharmacokinetic one. Semaglutide is metabolized by proteolytic cleavage, fatty acid oxidation, and renal excretion of small peptide fragments. It does not meaningfully inhibit or induce any cytochrome P450 enzyme at doses of 0.5 to 2.0 mg weekly, a fact confirmed in Novo Nordisk's clinical pharmacology package and reflected in the FDA-approved Ozempic prescribing information [1].

Trazodone, by contrast, relies on CYP3A4 as its primary metabolic pathway and CYP2D6 as a secondary route [2]. Because semaglutide does not touch either enzyme, it cannot raise or lower trazodone plasma levels.

Why Pharmacodynamic Overlap Still Matters

Even without PK interaction, two drugs can combine to produce effects neither would produce alone at typical doses. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that also blocks alpha-1 adrenergic and histamine-H1 receptors. Alpha-1 blockade causes vasodilation and orthostatic hypotension; H1 blockade adds sedation. Semaglutide's GLP-1 receptor agonism slows gastric emptying, causes nausea in roughly 15 to 20 percent of patients during the titration period, and can produce mild dehydration if vomiting or reduced fluid intake occurs [1].

Dehydration reduces circulating blood volume. Reduced blood volume amplifies trazodone's orthostatic drop. The sequence is predictable and clinically meaningful, particularly in older adults.

GLP-1 Receptors in the Central Nervous System

GLP-1 receptors are expressed in the hypothalamus, brainstem, and nucleus accumbens [3]. Semaglutide crosses the blood-brain barrier to a limited degree. Whether this CNS activity meaningfully compounds trazodone's sedative profile has not been studied in a controlled trial, but case series from GLP-1 receptor agonist use report increased somnolence in some patients during the first four to eight weeks of therapy. Prescribers should treat any patient-reported excessive daytime sedation as a signal warranting medication review.

Semaglutide's Pharmacokinetics: Why It Does Not Affect Trazodone Levels

Semaglutide reaches peak plasma concentration approximately one to three days after subcutaneous injection, with a half-life of approximately 165 hours (roughly seven days), allowing once-weekly dosing [1]. The molecule is a 34-amino-acid peptide analog of human GLP-1. Peptides of this size are not substrates, inhibitors, or inducers of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations seen in clinical use.

The Ozempic prescribing label explicitly states: "Semaglutide did not inhibit or induce any major CYP enzymes" [1]. This means a patient taking trazodone 100 mg at bedtime will see the same trazodone blood levels whether or not they are on Ozempic. Clinicians do not need to adjust trazodone doses on pharmacokinetic grounds.

P-glycoprotein and Drug Transporter Considerations

In vitro studies show semaglutide has minimal interaction with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters at therapeutic concentrations [1]. Trazodone is not a major P-gp substrate. Transporter-based interactions are therefore not a concern with this combination.

Gastric Emptying: The One PK Exception to Watch

Semaglutide slows gastric emptying. For most drugs, this produces only modest and clinically insignificant delays in time-to-peak concentration (Tmax). The FDA label notes that co-administration of semaglutide with oral medications requiring rapid absorption (for example, certain oral contraceptives and warfarin) warrants monitoring for changes in effect [1]. Trazodone is typically dosed at night and its sedative effect is tied to peak levels. A modest delay in gastric absorption of an oral trazodone dose could, in theory, shift the sedation peak slightly later into the night. This is rarely clinically new, but patients who notice that trazodone seems to "work later" after starting Ozempic should mention this to their prescriber.

Trazodone's Pharmacology and Why It Creates Interaction Risk

Trazodone is approved by the FDA for major depressive disorder and is widely used off-label for insomnia, often at doses of 25 to 100 mg [2]. Its multimodal mechanism includes:

• Serotonin reuptake inhibition (moderate potency)
• 5-HT2A receptor antagonism (primary antidepressant action)
• Alpha-1 adrenergic blockade (causes orthostasis)
• Histamine H1 antagonism (causes sedation)

Orthostatic Hypotension: The Dominant Risk

Alpha-1 blockade is the mechanism most relevant to the Ozempic combination. Blood pressure drops of 10 to 20 mmHg systolic on standing are reported in clinical trials of trazodone, particularly at doses above 150 mg [2]. In a patient already nauseated or dehydrated from Ozempic initiation, this drop can be large enough to cause dizziness, presyncope, or falls.

The risk is highest in:

• Adults over 65 years of age
• Patients with baseline low blood pressure (systolic <110 mmHg)
• Patients on antihypertensives (additive vasodilation)
• Patients in the first four to eight weeks of Ozempic titration, when GI side effects peak

Sedation Overlap and Next-Day Impairment

Trazodone's H1 blockade produces sedation lasting four to eight hours. GLP-1 receptor agonism in the brainstem may contribute to fatigue and nausea that reduces alertness. Together, they could impair morning driving or fine-motor work. Patients should be counseled not to take trazodone if they need to drive within eight hours.

QTc Prolongation: A Secondary Signal

The FDA drug safety communication for trazodone notes that trazodone may prolong the QT interval, particularly at high doses [2]. Semaglutide itself does not carry a primary QTc-prolongation warning, but the SUSTAIN-6 cardiovascular outcomes trial (N=3,297) noted no excess arrhythmia signal with semaglutide 0.5 to 1.0 mg over 104 weeks compared with placebo [4]. In patients with baseline QTc above 450 ms, or in those taking other QTc-prolonging agents, an ECG before and after trazodone initiation is a reasonable precaution.

Blood Glucose Interactions Between Semaglutide and Trazodone

How Semaglutide Controls Glucose

Semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. In the SUSTAIN-7 trial (N=1,201), semaglutide 1.0 mg reduced HbA1c by a mean of 1.8 percentage points versus 1.4 percentage points for dulaglutide 1.5 mg over 40 weeks (P<0.001) [5].

Trazodone's Effect on Blood Sugar

Trazodone is not classified as a drug that reliably alters glucose metabolism, but post-marketing reports and small observational studies associate serotonergic and antihistaminergic antidepressants with mild increases in fasting blood glucose through mechanisms that may include weight gain, increased cortisol reactivity, and reduced insulin sensitivity [6]. For most patients on low-dose trazodone for insomnia (25 to 100 mg), this effect is negligible. For patients with poorly controlled type 2 diabetes already requiring titration of their Ozempic dose, it is worth monitoring HbA1c at the three-month mark after adding trazodone.

Hypoglycemia Risk Is Low

Semaglutide does not cause hypoglycemia when used as monotherapy because insulin secretion is glucose-dependent; when blood glucose is normal, insulin release is not augmented. Trazodone does not stimulate insulin secretion. The combination therefore does not increase hypoglycemia risk unless the patient is also on a sulfonylurea or insulin. If sulfonylureas are part of the regimen, any nausea-induced meal skipping from Ozempic can increase hypoglycemia risk, but this is an Ozempic-sulfonylurea concern, not an Ozempic-trazodone concern.

Clinical Monitoring Protocol for the Ozempic-Trazodone Combination

The following stepwise monitoring framework reflects current guidance from the Endocrine Society's clinical practice guideline on obesity pharmacotherapy [7] and standard pharmacovigilance principles for orthostatic drugs.

Before Starting the Combination

1. Measure sitting and standing blood pressure and heart rate (orthostatic vital signs).
2. Review baseline QTc from a 12-lead ECG if the patient has cardiac history, electrolyte abnormalities, or is on other QTc-prolonging agents.
3. Record baseline fasting glucose or HbA1c.
4. Assess fall risk using the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) tool for patients 65 years or older [8].

During the First 8 Weeks of Ozempic Titration

Ozempic is initiated at 0.25 mg weekly for four weeks, then increased to 0.5 mg weekly. GI side effects peak during this window. Patients should be counseled to:

• Maintain adequate fluid intake (minimum 2 liters per day unless fluid restricted).
• Rise slowly from bed or a chair, pausing at the sitting position before standing.
• Avoid trazodone doses above 100 mg at bedtime during the first four weeks unless the prescribing psychiatrist has assessed orthostatic risk.
• Report any falls, near-fainting episodes, or marked daytime sedation within 48 hours.

Ongoing Monitoring

After the Ozempic dose has stabilized at 0.5 to 2.0 mg weekly and GI side effects have resolved:

• Repeat orthostatic vitals at the next scheduled visit.
• Check HbA1c at three months and six months.
• Ask specifically about sedation, falls, and morning impairment at every visit.

Special Populations

Older Adults

The American Geriatrics Society's 2023 Beers Criteria classifies trazodone as a potentially inappropriate medication in older adults due to orthostatic hypotension risk [9]. Adding Ozempic in a patient over 65 who is already on trazodone warrants a structured fall-risk review before the first injection. The Ozempic dose titration should proceed on schedule unless orthostatic symptoms develop.

Patients With Obesity (BMI <27 Not Met for Label Indication)

Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management in adults with BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity [10]. Ozempic (0.5 to 2.0 mg) is approved for type 2 diabetes. Patients using Ozempic off-label for weight loss who are concurrently on trazodone for depression or insomnia represent a common telehealth scenario. The same monitoring framework applies regardless of the prescribing indication.

Patients With Hepatic Impairment

Trazodone clearance decreases in moderate-to-severe hepatic impairment, raising plasma levels and amplifying both sedation and orthostatic effects [2]. Semaglutide pharmacokinetics are not materially altered by hepatic impairment [1]. In a patient with liver disease on both drugs, lower starting doses of trazodone (25 mg) are appropriate.

Patient Counseling Points

Clear counseling language matters as much as the clinical data. Prescribers and clinical pharmacists should communicate the following points in plain terms:

On timing of doses. Take trazodone at bedtime, not during the day, to separate its sedative peak from daytime activity. Ozempic is injected once weekly; the day of the week can be any day the patient chooses, and it does not need to be timed around trazodone.

On hydration. Nausea from Ozempic leads some patients to drink less fluid. Dehydration worsens trazodone's blood-pressure-lowering effect. Encourage sips of water, broth, or electrolyte drinks even when nauseated.

On rising from bed. Postural dizziness peaks in the first 30 seconds of standing. Patients should sit upright for 30 seconds before standing, then stand slowly. This simple maneuver can prevent most falls.

On alcohol. Both drugs increase sedation risk with alcohol. Patients should avoid alcohol, particularly in the first two months of Ozempic therapy when GI effects are most pronounced.

On driving. Patients starting or increasing trazodone dose should not drive until they know how sedated they feel in the morning. Ozempic itself rarely causes sedation severe enough to impair driving, but nausea can be distracting.

What Prescribers Often Miss: The Nausea-Dehydration-Orthostasis Chain

Most drug interaction databases flag the Ozempic-trazodone pair as "minor" or "monitor only" without explaining the clinical cascade that makes it occasionally serious. The chain looks like this:

Ozempic initiation or dose increase produces nausea. Nausea reduces fluid intake and may cause vomiting. Reduced fluid intake contracts intravascular volume by as little as 300 to 500 mL. Trazodone's alpha-1 blockade, which normally produces a modest 10 mmHg systolic orthostatic drop, now produces a 20 to 30 mmHg drop in a volume-contracted patient. The patient stands after taking trazodone at night to use the bathroom and falls.

This chain is not theoretical. The FDA's Adverse Event Reporting System (FAERS) contains fall and syncope reports for both GLP-1 receptor agonists and trazodone individually. The CDC reports that 36 million falls occur annually in U.S. Adults over 65, and polypharmacy involving orthostatic agents is among the top modifiable risk factors [8].

The clinical instruction that prevents this: counsel every patient starting Ozempic who is also on trazodone to drink at least 500 mL of fluid before bed and to use a bedside commode or sit-to-stand technique at night during the first six weeks of therapy.

Summary of Interaction Severity and Action Required

| Parameter | Detail | |---|---| | Interaction type | Pharmacodynamic (not PK) | | Severity | Moderate | | Mechanism | Alpha-1 blockade plus dehydration from GLP-1 GI effects | | Requires dose change | No (titrate Ozempic per standard schedule) | | Requires monitoring | Yes: orthostatic BP, HR, HbA1c, fall risk, QTc if indicated | | Contraindicated | No | | Most at-risk population | Adults 65+, baseline low BP, concurrent antihypertensives |